Targeted Therapies in Adult B-Cell Malignancies

Abstract : B-lymphocytes are programmed for the production of immunoglobulin (Ig) after antigen presentation, in the context of T-lymphocyte control within lymphoid organs. During this differentiation/activation process, B-lymphocytes exhibit different restricted or common surface markers, activation of cellular pathways that regulate cell cycle, metabolism, proteasome activity, and protein synthesis. All molecules involved in these different cellular mechanisms are potent therapeutic targets. Nowadays, due to the progress of the biology, more and more targeted drugs are identified, a situation that is correlated with an extended field of the targeted therapy. The full knowledge of the cellular machinery and cell-cell communication allows making the best choice to treat patients, in the context of personalized medicine. Also, focus should not be restricted to the immediate effects observed as clinical endpoints, that is, response rate, survival markers with conventional statistical methods, but it should consider the prediction of different clinical consequences due to other collateral drug targets, based on new methodologies. This means that new reflection and new bioclinical follow-up have to be monitored, particularly with the new drugs used with success in B-cell malignancies. This review discussed the principal aspects of such evident bioclinical progress.
Liste complète des métadonnées
Contributeur : Cécile Nowak <>
Soumis le : mardi 4 décembre 2018 - 13:47:30
Dernière modification le : mardi 28 mai 2019 - 10:42:02

Lien texte intégral




Jean-François Rossi. Targeted Therapies in Adult B-Cell Malignancies. BioMed Research International , Hindawi Publishing Corporation, 2015, 2015, pp.1-16. ⟨10.1155/2015/217593⟩. ⟨hal-01944067⟩



Consultations de la notice